Back to Search Start Over

Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases.

Authors :
Araujo-Castro, Marta
Biagetti, Betina
Torre, Edelmiro Menéndez
Novoa-Testa, Iría
Cordido, Fernando
Corrales, Eider Pascual
Berrocal, Víctor Rodríguez
Guerrero-Pérez, Fernando
Vicente, Almudena
Percovich, Juan Carlos
Centeno, Rogelio García
González, Laura
García, María Dolores Ollero
Echarri, Ana Irigaray
Rodríguez, María Dolores Moure
Novo-Rodríguez, Cristina
Calatayud, María
Villar, Rocío
Bernabéu, Ignacio
Alvarez-Escola, Cristina
Source :
Journal of Clinical Endocrinology & Metabolism; Dec2024, Vol. 109 Issue 12, pe2178-e2187, 10p
Publication Year :
2024

Abstract

Context Few data exist about the clinical course of acromegaly, surgical and medical outcomes in patients with GH- and prolactin cosecreting pituitary adenomas (GH&PRL-PAs). Nevertheless, some series described a more aggressive clinic-radiological behavior than in growth hormone–secreting pituitary adenomas (GH-PAs). Objective This work aims to evaluate differences in clinical presentation and in surgical outcomes between GH-PAs and GH&PRL-PAs. Methods A multicenter retrospective study was conducted of 604 patients with acromegaly who underwent pituitary surgery. Patients were classified into 2 groups according to serum PRL levels at diagnosis and immunohistochemistry (IHC) for PRL: a) GH&PRL-PAs when PRL levels were above the upper limit of normal (ULN) and IHC for GH and PRL was positive or PRL levels were greater than 100 ng/dL and PRL IHC was not available (n = 130) and b) GH-PA patients who did not meet the previously mentioned criteria (n = 474). Results GH&PRL-PAs represented 21.5% (n = 130) of patients with acromegaly. The mean age at diagnosis was lower in GH&PRL-PAs than in GH-PAs (P <.001). GH&PRL-PAs were more frequently macroadenomas (90.6% vs 77.4%; P =.001) and tended to be more invasive (33.6% vs 24.7%; P =.057) than GH-PAs. Furthermore, they had presurgical hypopituitarism more frequently (odds ratio 2.8; 95% CI, 1.83-4.38). Insulin-like growth factor ULN levels at diagnosis were lower in patients with GH&PRL-PAs (median 2.4 [interquartile range (IQR) 1.73-3.29] vs 2.7 [IQR 1.91-3.67]; P =.023). There were no differences in the immediate (41.1% vs 43.3%; P =.659) or long-term postsurgical acromegaly biochemical cure rate (53.5% vs 53.1%; P =.936) between groups. However, there was a higher incidence of permanent arginine-vasopressin deficiency (AVP-D) (7.3% vs 2.4%; P =.011) in GH&PRL-PA patients. Conclusion GH&PRL-PAs are responsible for 20% of acromegaly cases. These tumors are more invasive, larger, and cause hypopituitarism more frequently than GH-PAs and are diagnosed at an earlier age. The biochemical cure rate is similar between both groups, but patients with GH&PRL-PAs tend to develop permanent postsurgical AVP-D more frequently. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0021972X
Volume :
109
Issue :
12
Database :
Complementary Index
Journal :
Journal of Clinical Endocrinology & Metabolism
Publication Type :
Academic Journal
Accession number :
181096317
Full Text :
https://doi.org/10.1210/clinem/dgae126